Hospital Acquired Disease Testing Market Size, Share, Trends, Growth Outlook

Hospital Acquired Disease Testing Market is estimated to increase at a growth rate of 7.8% CAGR over the forecast period from 2024 to 2030.

The Hospital Acquired Disease Testing Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Test (Urinary Tract Infection, Surgical Site Infection, Pneumonia Stents, Blood Stream Infection, Methicillin-Resistant Staphylococcus Aureus, Others), By End-User (Hospitals and Intensive Care Units (ICUS), Ambulatory Surgical and Diagnostic Centers, Nursing Homes, Maternity Centers).

An Introduction to Hospital Acquired Disease Testing Market in 2024

The Hospital Acquired Disease Testing market in 2024 is experiencing significant growth driven by the increasing focus on infection control, antimicrobial stewardship, and patient safety initiatives in healthcare facilities worldwide. Hospital-acquired diseases, also known as healthcare-associated infections (HAIs), pose a significant threat to patient health and contribute to increased morbidity, mortality, and healthcare costs. The market offers a diverse range of diagnostic tests and surveillance solutions to identify and monitor HAIs, including bloodstream infections, urinary tract infections, surgical site infections, and ventilator-associated pneumonia. With factors such as antibiotic resistance, regulatory mandates, and quality accreditation requirements driving demand for rapid and accurate diagnostic solutions, hospitals are investing in advanced testing technologies, automation systems, and data analytics tools to enhance infection prevention and control practices, reduce transmission rates, and improve patient outcomes. Moreover, with the emergence of novel pathogens and infectious disease threats, the hospital-acquired disease testing market is poised for continued innovation, collaboration, and investment in research and development efforts aimed at addressing evolving healthcare challenges and safeguarding patient health.

Hospital Acquired Disease Testing Market Trend: Rise in Hospital-Acquired Infections Awareness

A prominent trend in the hospital-acquired disease testing market is the increasing awareness and focus on hospital-acquired infections (HAIs). Healthcare facilities are increasingly prioritizing infection control measures to mitigate the risk of HAIs, which pose significant challenges to patient safety, healthcare delivery, and healthcare costs. As HAIs continue to be a major concern globally, there is a growing demand for comprehensive testing solutions and protocols to detect and prevent the spread of infectious pathogens within healthcare settings. This trend reflects the industry's efforts to address the growing incidence of HAIs and improve infection control practices in hospitals and healthcare facilities.

Hospital Acquired Disease Testing Market Driver: Regulatory Mandates and Quality Standards

A key driver in the hospital-acquired disease testing market is the implementation of regulatory mandates and quality standards aimed at reducing HAIs. Regulatory bodies and healthcare organizations worldwide have established guidelines, protocols, and performance metrics to ensure compliance with infection control measures and improve patient safety outcomes. These mandates often require routine testing and surveillance for infectious pathogens such as bacteria, viruses, and fungi in hospital environments, including patient rooms, surgical suites, and medical equipment. The emphasis on adherence to regulatory requirements and accreditation standards drives market demand for hospital-acquired disease testing solutions that enable healthcare facilities to meet regulatory compliance, enhance infection prevention strategies, and minimize the risk of HAIs.

Hospital Acquired Disease Testing Market Opportunity: Development of Rapid Diagnostic Tests

An opportunity for growth in the hospital-acquired disease testing market lies in the development of rapid diagnostic tests (RDTs) for HAIs. Traditional laboratory-based testing methods often involve time-consuming sample processing, culture incubation, and microbial identification, leading to delays in diagnosis and treatment initiation for patients at risk of HAIs. By investing in research and development of RDTs, manufacturers can offer innovative testing solutions that deliver rapid and accurate results for common pathogens associated with HAIs, such as methicillin-resistant Staphylococcus aureus (MRSA), Clostridioides difficile (C. difficile), and multidrug-resistant organisms (MDROs). RDTs enable timely detection of infectious pathogens, prompt implementation of infection control measures, and targeted antimicrobial therapy, thereby reducing the transmission of HAIs, improving patient outcomes, and optimizing resource utilization in healthcare settings. This opportunity aligns with the industry's focus on advancing diagnostic technologies and enhancing infection control practices to combat HAIs effectively.

Hospital Acquired Disease Testing Market Segmentation

By Test
Urinary Tract Infection
Surgical Site Infection
Pneumonia Stents
Blood Stream Infection
Methicillin-Resistant Staphylococcus Aureus
Others
By End-User
Hospitals and Intensive Care Units (ICUS)
Ambulatory Surgical and Diagnostic Centers
Nursing Homes
Maternity Centers
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Hospital Acquired Disease Testing Market Companies

3M
Abbott
Becton, Dickinson and Company
BIOMÉRIEUX
Cantel Medical
Cepheid Inc
Diatherix Laboratories
Eurofins Scientific
F. Hoffmann-La Roche Ltd
Getinge AB
Hologic Inc
Life Technologies
Luminex Corp
Medtronic
Meridian Bioscience Inc
Olympus Corp
QIAGEN
Siemens Healthcare Private Ltd
Thermo Fisher Scientific Inc

 

 

Reasons to Buy the Hospital Acquired Disease Testing Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Hospital Acquired Disease Testing Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Hospital Acquired Disease Testing Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

 

TABLE OF CONTENTS

1 Introduction to 2024 Hospital Acquired Disease Testing Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Hospital Acquired Disease Testing Market Size Outlook, $ Million, 2021 to 2030
3.2 Hospital Acquired Disease Testing Market Outlook by Type, $ Million, 2021 to 2030
3.3 Hospital Acquired Disease Testing Market Outlook by Product, $ Million, 2021 to 2030
3.4 Hospital Acquired Disease Testing Market Outlook by Application, $ Million, 2021 to 2030
3.5 Hospital Acquired Disease Testing Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Hospital Acquired Disease Testing Market Industry
4.2 Key Market Trends in Hospital Acquired Disease Testing Market Industry
4.3 Potential Opportunities in Hospital Acquired Disease Testing Market Industry
4.4 Key Challenges in Hospital Acquired Disease Testing Market Industry

5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Hospital Acquired Disease Testing Market Share by Company (%), 2023
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Hospital Acquired Disease Testing Market Outlook By Segments
7.1 Hospital Acquired Disease Testing Market Outlook by Segments
By Test
Urinary Tract Infection
Surgical Site Infection
Pneumonia Stents
Blood Stream Infection
Methicillin-Resistant Staphylococcus Aureus
Others
By End-User
Hospitals and Intensive Care Units (ICUS)
Ambulatory Surgical and Diagnostic Centers
Nursing Homes
Maternity Centers

8 North America Hospital Acquired Disease Testing Market Analysis And Outlook To 2030
8.1 Introduction to North America Hospital Acquired Disease Testing Markets in 2024
8.2 North America Hospital Acquired Disease Testing Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Hospital Acquired Disease Testing Market size Outlook by Segments, 2021-2030
By Test
Urinary Tract Infection
Surgical Site Infection
Pneumonia Stents
Blood Stream Infection
Methicillin-Resistant Staphylococcus Aureus
Others
By End-User
Hospitals and Intensive Care Units (ICUS)
Ambulatory Surgical and Diagnostic Centers
Nursing Homes
Maternity Centers

9 Europe Hospital Acquired Disease Testing Market Analysis And Outlook To 2030
9.1 Introduction to Europe Hospital Acquired Disease Testing Markets in 2024
9.2 Europe Hospital Acquired Disease Testing Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Hospital Acquired Disease Testing Market Size Outlook By Segments, 2021-2030
By Test
Urinary Tract Infection
Surgical Site Infection
Pneumonia Stents
Blood Stream Infection
Methicillin-Resistant Staphylococcus Aureus
Others
By End-User
Hospitals and Intensive Care Units (ICUS)
Ambulatory Surgical and Diagnostic Centers
Nursing Homes
Maternity Centers

10 Asia Pacific Hospital Acquired Disease Testing Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Hospital Acquired Disease Testing Markets in 2024
10.2 Asia Pacific Hospital Acquired Disease Testing Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Hospital Acquired Disease Testing Market size Outlook by Segments, 2021-2030
By Test
Urinary Tract Infection
Surgical Site Infection
Pneumonia Stents
Blood Stream Infection
Methicillin-Resistant Staphylococcus Aureus
Others
By End-User
Hospitals and Intensive Care Units (ICUS)
Ambulatory Surgical and Diagnostic Centers
Nursing Homes
Maternity Centers

11 South America Hospital Acquired Disease Testing Market Analysis And Outlook To 2030
11.1 Introduction to South America Hospital Acquired Disease Testing Markets in 2024
11.2 South America Hospital Acquired Disease Testing Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Hospital Acquired Disease Testing Market size Outlook by Segments, 2021-2030
By Test
Urinary Tract Infection
Surgical Site Infection
Pneumonia Stents
Blood Stream Infection
Methicillin-Resistant Staphylococcus Aureus
Others
By End-User
Hospitals and Intensive Care Units (ICUS)
Ambulatory Surgical and Diagnostic Centers
Nursing Homes
Maternity Centers

12 Middle East And Africa Hospital Acquired Disease Testing Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Hospital Acquired Disease Testing Markets in 2024
12.2 Middle East and Africa Hospital Acquired Disease Testing Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Hospital Acquired Disease Testing Market size Outlook by Segments, 2021-2030
By Test
Urinary Tract Infection
Surgical Site Infection
Pneumonia Stents
Blood Stream Infection
Methicillin-Resistant Staphylococcus Aureus
Others
By End-User
Hospitals and Intensive Care Units (ICUS)
Ambulatory Surgical and Diagnostic Centers
Nursing Homes
Maternity Centers

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
3M
Abbott
Becton, Dickinson and Company
BIOMÉRIEUX
Cantel Medical
Cepheid Inc
Diatherix Laboratories
Eurofins Scientific
F. Hoffmann-La Roche Ltd
Getinge AB
Hologic Inc
Life Technologies
Luminex Corp
Medtronic
Meridian Bioscience Inc
Olympus Corp
QIAGEN
Siemens Healthcare Private Ltd
Thermo Fisher Scientific Inc

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Test
Urinary Tract Infection
Surgical Site Infection
Pneumonia Stents
Blood Stream Infection
Methicillin-Resistant Staphylococcus Aureus
Others
By End-User
Hospitals and Intensive Care Units (ICUS)
Ambulatory Surgical and Diagnostic Centers
Nursing Homes
Maternity Centers